Skip to main content
Premium Trial:

Request an Annual Quote

Omicia Rebrands as Fabric Genomics, Inks Strategic Partnership With Sentieon

NEW YORK (GenomeWeb) – The bioinformatics company formerly known as Omicia announced today that it will now be known as Fabric Genomics, and that it is launching a new end-to-end clinical genomics platform called Fabric Enterprise.

The Oakland, California-based firm also announced that it has signed a technology partnership agreement with bioinformatics firm Sentieon to enhance the platform's secondary analysis capabilities. The firms will co-develop new variant calling software for hereditary diseases and oncology with the aim of improving accuracy.

Adding Sentieon's algorithms to Fabric Enterprise "marks a broad expansion in our capabilities as a company and provides our customers with the option to work with one software partner for all their NGS testing needs," Fabric Genomics CEO Matt Tindall said in a statement.

"We anticipate opportunities to build important and powerful new applications with the Fabric Genomics team," added Sentieon CEO Jun Ye.

Fabric and Sentieon also said they will develop structural variant and copy number variant capabilities for genomic analysis built upon Sentieon's tools and Fabric Genomics' BioGraph technology.

This year has been one of change for Fabric. In January, the company acquired variant detection software firm Spiral Genetics for an undisclosed sum.

"As a result of our recent acquisition, related capability expansions, and technology partnerships, it was time to reimagine our company's broader role in the future of healthcare," Tindall said. "Our role, along with our partners, is to secure, manage, analyze, interpret, and weave genetic data into the fabric of healthcare to drive behavior change, cost efficiency, and better outcomes. The idea that we can unlock genetic information unlike any other company, to inform important healthcare decisions, gave rise to Fabric Genomics."

The Scan

CRISPR Screens Reveal Heart Attack-Linked Gene

Researchers in PLOS Genetics have used CRISPR screens to home in on variants associated with coronary artery disease that affect vascular endothelial function.

Meta AI Computer Model Rapidly Predicts Hundreds of Millions of Metagenomic Proteins

Meta AI researchers describe in Science a new large language model that can predict the structures of millions of metagenomic proteins.

Hutch Team Develops Platform for Assessing Impact of SARS-CoV-2 Spike Mutations

The approach described in Cell relies on lentiviral pseudotyping for mutational scanning, which the researchers applied to the SARS-CoV-2 spike protein.

Potential New Therapeutic Target for Rheumatoid Arthritis Discovered

Researchers report in the American Journal of Human Genetics that SNPs implicated in rheumatoid arthritis often regulate the expression of the inflammation-related SPRED2 gene.